PROK · Company research
ProKidney Corp. Class A Ordinary Shares (PROK): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
18records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| ProKidney (NASDAQ:PROK) Stock Price Down 6% - Here's Why - MarketBeat | ProKidney (NASDAQ:PROK) Stock Price Down 6% - Here's Why MarketBeat | View source ↗ | MarketBeat | Oct 14, 2026 | neutral | 0 | 0.6 |
| ProKidney Corp. (PROK) Slips 2.05% to $1.68 as Shares Sit Mid-Range Between Key Levels - Growth ETF - https://www.siam.in/ | ProKidney Corp. (PROK) Slips 2.05% to $1.68 as Shares Sit Mid-Range Between Key Levels - Growth ETF https://www.siam.in/ | View source ↗ | https://www.siam.in/ | Oct 2, 2026 | neutral | 0 | 0.6 |
| ProKidney Announces Eight Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2026 | ProKidney announced that eight abstracts, including one oral presentation, will be presented at ASN's Kidney Week 2026 in Denver. The abstracts present translational research and a pooled Phase 2 analysis supporting rilparencel's multifactorial mechanism of action for treating chronic kidney disease with type 2 diabetes, demonstrating kidney function stabilization and a strong safety profile. | View source ↗ | GlobeNewswire Inc. | Oct 2, 2026 | bullish | 1 | 1 |
| ProKidney Announces Eight Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2026 | ProKidney announced that eight abstracts, including one oral presentation, will be presented at ASN's Kidney Week 2026 in Denver. The abstracts present translational research and a pooled Phase 2 analysis supporting rilparencel's multifactorial mechanism of action for treating chronic kidney disease with type 2 diabetes, demonstrating kidney function stabilization and a strong safety profile. | View source ↗ | GlobeNewswire Inc. | Oct 2, 2026 | bullish | 1 | 1 |
| A kidney cell therapy study points to stable function in advanced disease - Stock Titan | A kidney cell therapy study points to stable function in advanced disease Stock Titan | View source ↗ | Stock Titan | Oct 2, 2026 | neutral | 0 | 0.6 |
| ProKidney (NASDAQ:PROK) Stock Price Down 7.6% - Should You Sell? - MarketBeat | ProKidney (NASDAQ:PROK) Stock Price Down 7.6% - Should You Sell? MarketBeat | View source ↗ | MarketBeat | Sep 21, 2026 | neutral | 0 | 0.6 |
| PROK Stock Holds Tight Range As Traders Weigh Deep Losses Against Strong Cash - timothysykes.com | PROK Stock Holds Tight Range As Traders Weigh Deep Losses Against Strong Cash timothysykes.com | View source ↗ | timothysykes.com | Sep 19, 2026 | neutral | 0 | 0.6 |
| Keep An Eye On ProKidney As Insider Stock Selling Hits US$3.0m - Moomoo | Keep An Eye On ProKidney As Insider Stock Selling Hits US$3.0m Moomoo | View source ↗ | Moomoo | Aug 26, 2026 | neutral | 0 | 0.6 |
| $PROK stock is up 7% today. Here's what we see in our data. - Quiver Quantitative | $PROK stock is up 7% today. Here's what we see in our data. Quiver Quantitative | View source ↗ | Quiver Quantitative | Aug 21, 2026 | neutral | 0 | 0.6 |
| ProKidney Corp. Class A (PROK) Stock Price & News - Syfe | ProKidney Corp. Class A (PROK) Stock Price & News Syfe | View source ↗ | Syfe | Aug 20, 2026 | neutral | 0 | 0.6 |
| ProKidney (NASDAQ: PROK) director plans new restricted stock sale - Stock Titan | ProKidney (NASDAQ: PROK) director plans new restricted stock sale Stock Titan | View source ↗ | Stock Titan | Aug 18, 2026 | neutral | 0 | 0.6 |
| ProKidney: Do-Or-Die Phase 3 Meets A Dwindling Balance Sheet (Rating Downgrade) (PROK) - Seeking Alpha | ProKidney: Do-Or-Die Phase 3 Meets A Dwindling Balance Sheet (Rating Downgrade) (PROK) Seeking Alpha | View source ↗ | Seeking Alpha | Aug 14, 2026 | neutral | 0 | 0.6 |
| ProKidney Corp. (PROK) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance | ProKidney Corp. (PROK) Reports Q2 Loss, Misses Revenue Estimates Yahoo Finance | View source ↗ | Yahoo Finance | Aug 10, 2026 | neutral | 0 | 0.6 |
| July 2026 Penny Stocks With Promising Potential - Simply Wall Street | July 2026 Penny Stocks With Promising Potential Simply Wall Street | View source ↗ | Simply Wall Street | Jul 6, 2026 | neutral | 0 | 0.6 |
| PROK Forecast — Price Target — Prediction for 2027 - TradingView | PROK Forecast — Price Target — Prediction for 2027 TradingView | View source ↗ | TradingView | Jun 25, 2026 | neutral | 0 | 0.6 |
| Why ProKidney (PROK) Is Building Its Bull Case Around Rilparencel’s Accelerated Approval Path - Yahoo Finance | Why ProKidney (PROK) Is Building Its Bull Case Around Rilparencel’s Accelerated Approval Path Yahoo Finance | View source ↗ | Yahoo Finance | Jun 17, 2026 | neutral | 0 | 0.6 |
| ProKidney Corp. (PROK) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance | ProKidney Corp. (PROK) Reports Q1 Loss, Tops Revenue Estimates Yahoo Finance | View source ↗ | Yahoo Finance | May 15, 2026 | neutral | 0 | 0.6 |
| ProKidney Stock: Differentiated CKD Approach Positions Rilparencel Favorably (NASDAQ:PROK) - Seeking Alpha | ProKidney Stock: Differentiated CKD Approach Positions Rilparencel Favorably (NASDAQ:PROK) Seeking Alpha | View source ↗ | Seeking Alpha | Jan 31, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.